Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Selective immunointervention in autoimmune diseases: lessons from multiple sclerosis.

L Adorini1

  • 1Roche Milano Ricerche, Italy. luciano.adorini@roche.com

Journal of Chemotherapy (Florence, Italy)
|July 14, 2001
PubMed
Summary

T cell activation is tightly regulated by deletion, anergy, and suppression to prevent autoimmune diseases. New strategies for selective immunosuppression show promise for treating conditions like multiple sclerosis (MS).

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Protective effect of UDCA against IL-11- induced cardiac fibrosis is mediated by TGR5 signalling.

Frontiers in cardiovascular medicine·2024
Same author

Farnesoid X receptor activation by the novel agonist TC-100 (3α, 7α, 11β-Trihydroxy-6α-ethyl-5β-cholan-24-oic Acid) preserves the intestinal barrier integrity and promotes intestinal microbial reshaping in a mouse model of obstructed bile acid flow.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie·2022
Same author

The FXR agonist obeticholic acid inhibits the cancerogenic potential of human cholangiocarcinoma.

PloS one·2019
Same author

Therapeutic effects of the selective farnesoid X receptor agonist obeticholic acid in a monocrotaline-induced pulmonary hypertension rat model.

Journal of endocrinological investigation·2019
Same author

Therapeutic effects of obeticholic acid (OCA) treatment in a bleomycin-induced pulmonary fibrosis rat model.

Journal of endocrinological investigation·2018
Same author

Differential effects of FXR or TGR5 activation in cholangiocarcinoma progression.

Biochimica et biophysica acta. Molecular basis of disease·2017

Area of Science:

  • Immunology
  • Autoimmunity
  • Immunotherapy

Background:

  • T cell activation by foreign and self-antigens is strictly controlled by thymic and peripheral mechanisms.
  • Failure in T cell regulation (deletion, anergy, suppression) can lead to autoimmune diseases.
  • Current immunosuppressive drugs have limited efficacy, selectivity, and significant toxicity, highlighting a need for better treatments.

Purpose of the Study:

  • To review advances in selective immunointervention strategies for autoimmune diseases.
  • To examine the application of these strategies in multiple sclerosis (MS) as a model.
  • To assess successes and failures of current immunotherapeutic approaches in human autoimmune diseases.

Main Methods:

  • Identification of key targets for selective immunointervention.

Related Experiment Videos

  • Exploration of strategies including antigen recognition modulation, co-stimulation blockade, and regulatory cell induction.
  • Evaluation of cytokine-based therapies and leukocyte trafficking modulation.
  • Review of experimental autoimmune disease models and human clinical applications.

    • Main Results:

    • Multiple immunointervention strategies have shown success in preventing and treating experimental autoimmune diseases.
    • Key attack points for selective immunointervention have been identified.
    • Advances in understanding T cell modulation are paving the way for new therapeutic approaches.

    Conclusions:

    • Selective immunosuppression holds significant potential for treating autoimmune diseases, allergies, and allograft rejection.
    • Multiple sclerosis serves as a crucial paradigm for evaluating the efficacy and limitations of immunotherapeutic strategies.
    • Translating experimental successes into effective human therapies remains an ongoing challenge.